International Chemical Investors Group (ICIG) has entered into an agreement for to acquire Roche Colorado Corp., which includes Roche’s pharmaceutical production facility in Boulder, CO. The acquisition covers approximately 265 employees and includes technical development and small molecule manufacturing capabilities. Financial terms were not disclosed.

ICIG plans to operate the Boulder site as Corden Pharma Colorado Inc., a component of its Corden Pharma organization; it will initially supply Roche with a number of API that the Boulder site currently produces.

“Selling the Boulder site to ICIG will secure a reliable supplier to meet Roche’s demand for commercial scale peptides and other medicinal compounds,” said Dr. Georg Wiebecke, the head of Chemical Manufacturing for Roche. “We also are pleased to identify a buyer that will create a sustainable future for the Boulder site.”

According to an ICIG statement, Roche’s Boulder facility is “a global leader in the production of therapeutic peptide compounds, having pioneered large scale synthetic manufacturing technologies.” The site also maintains capabilities in the production of complex small molecules and highly potent compounds.

“By purchasing the Boulder facility, we position ourselves for a commanding presence in the contract peptide manufacturing industry,” said Dr. Wolfgang Niedermaier, the president of Corden Pharma. “We are excited to expand the market for the Boulder site’s unique technical capabilities, attracting additional API production opportunities that will build on its existing portfolio of Roche products and other pharmaceutical contract business.”